LIPAGLYN Trademark

Trademark Overview

On Tuesday, April 20, 2021, a trademark application was filed for LIPAGLYN with the United States Patent and Trademark Office. The USPTO has given the LIPAGLYN trademark a serial number of 90658433. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Thursday, September 5, 2024. This trademark is owned by Cadila Healthcare Limited. The LIPAGLYN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for use in the treatment of Diabetes, Dyslipidemia, NASH, Hypertriglycedemia and HIV-induced lipodystrophy
lipaglyn

General Information

Serial Number90658433
Word MarkLIPAGLYN
Filing DateTuesday, April 20, 2021
Status734 - FIFTH EXTENSION - GRANTED
Status DateThursday, September 5, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 18, 2022

Trademark Statements

Goods and ServicesPharmaceutical preparations for use in the treatment of Diabetes, Dyslipidemia, NASH, Hypertriglycedemia and HIV-induced lipodystrophy

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, July 28, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCadila Healthcare Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressGujarat Ahmedabad
IN
Party NameCadila Healthcare Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGujarat Ahmedabad
IN

Trademark Events

Event DateEvent Description
Friday, April 23, 2021NEW APPLICATION ENTERED
Wednesday, July 28, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, December 13, 2021ASSIGNED TO EXAMINER
Monday, December 13, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, January 18, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, December 29, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 18, 2022PUBLISHED FOR OPPOSITION
Tuesday, March 15, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, August 5, 2022SOU TEAS EXTENSION RECEIVED
Friday, August 5, 2022SOU EXTENSION 1 FILED
Friday, August 5, 2022SOU EXTENSION 1 GRANTED
Wednesday, September 13, 2023SOU EXTENSION 3 FILED
Tuesday, August 9, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 14, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, March 14, 2023SOU EXTENSION 2 FILED
Tuesday, March 14, 2023SOU EXTENSION 2 GRANTED
Thursday, March 16, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 13, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, September 13, 2023SOU EXTENSION 3 GRANTED
Tuesday, February 20, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, February 20, 2024SOU EXTENSION 4 GRANTED
Tuesday, February 20, 2024SOU EXTENSION 4 FILED
Thursday, September 5, 2024SOU TEAS EXTENSION RECEIVED
Thursday, September 5, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 5, 2024SOU EXTENSION 5 FILED
Thursday, September 5, 2024SOU EXTENSION 5 GRANTED
Wednesday, February 21, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, September 15, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

lipaglyn hypertriglycedemia induced lipodystrophy nash dyslipidemia preparations treatment diabetes pharmaceutical